http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102198099-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b8f22aecbd06c70c8efe00ae4aa237e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02 |
| filingDate | 2011-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3805a20399cd11c8d99e70f85273cd2f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52730c167f74ad85126b9a01012a5eed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed0f0793965e7b1f5683f06e31c7c186 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2433b5de07ad60743ecab7689d77a278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_919e28587e33f73b3fae8661926b3e21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a6398fe6e45b43430530c7e16378e19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d6677857d8502ddf19f8d623f0c9589 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8e2502a2253b1a046eb6abbd67c4871 |
| publicationDate | 2014-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102198099-B |
| titleOfInvention | Toltrazuril suspension and preparation method thereof |
| abstract | The invention discloses toltrazuril suspension, which belongs to the field of veterinary medicines and comprises the following components in percentage by mass: 2.5 to 15 percent of toltrazuril, 15.0 to 30.0 percent of suspending aid, and 65.0 to 82.5 percent of auxiliary materials. The invention also discloses the preparation method of the suspension. The suspension is administrated by mixing with drinking water, the use is convenient, the suspension is suitable for mass administration, and the labor force and materials are saved; the dosage is accurate, the toltrazuril disperses uniformly in water, and the concentration of the medicine is uniform; the absorption of the toltrazuril is desirable, the effectiveness is quick, and the bioavailability is high; in addition, compared with liquid preparation, the toltrazuril suspension is very stable and maintains a dry state constantly in a process from production to storage, and the package is sealed to prevent the suspension from contact with moisture and air. The suspension does not contain organic solvent, so the possibility of adverse pharmacological effect that may be produced by the organic solvent is lowered and the safety is high. |
| priorityDate | 2011-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.